The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

Scientists believe this is the first series demonstrating a significant survival difference in patients monitored with an intensive follow-up strategy via 18F-fludeoxyglucose–positron emission tomography.  

Given the approach’s “superior prognostic value,” experts urged for the incorporation of tau PET into routine clinical evaluation in memory care clinics. 

New research, presented at SNMMI 2023, details how the brains of obese individuals differ from those who maintain a healthy weight.  

This year the Henry N. Wagner Jr., Image of the Year is actually a group of images displaying the efficacy of a 68Ga-DOTA-5G and 177Lu-DOTA-ABM-5G theranostic pairing that improves the detection and treatment of metastatic pancreatic cancer. 

The new technology achieves this by way of two add-on detectors that simultaneously scan patients during their whole-body PET exam.

Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.